Loading clinical trials...

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo | Clinical Trials | Clareo Health

COMPLETEDNA

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo

NCT02661438•Bayer

View on ClinicalTrials.gov

Summary

The rationale of this study is to conduct a summative (i.e., validation) usability test of Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects (male and female) with non-cystic fibrosis bronchiectasis (NCFB) or chronic obstructive pulmonary disease (COPD)
•Subjects must be aged ≥40
•Subject must be able to independently manage and administer their NCFB/COPD medications

Exclusion Criteria

•Subjects with recent exacerbation
•Subjects with recent significant hemoptysis in the four weeks before screening (and/or during the screening period)
•Subjects allergic to quinine
•Known chronic bronchial asthma

Locations (2)

Vero Beach, Florida, United States

Jamaica, New York, United States

Key Dates

Start Date

January 12, 2016

Primary Completion Date

March 17, 2016

Completion Date

March 17, 2016

Last Updated

December 19, 2018

Enrollment

ACTUAL participants

Conditions

BronchiectasisPulmonary Disease, Chronic Obstructive

Interventions

Placebo to Ciprofloxacin DPI (BAYQ3939)

DRUG

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056

Bronchiectasis

View study

RECRUITING

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

NCT02779478

Nontuberculous MycobacteriaBronchiectasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

A Clinical Study of RSS0343 in Healthy Subjects

Role of BARriers in IgG-Pathogen Interactions at the Mucosal Surface in Human Airways

Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)